To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
The MMEDS Act of 2025 creates tax credits to bring medical manufacturing to economically distressed areas of the United States and its territories. Manufacturers operating qualified medical manufacturing facilities in these zones receive a 40% tax credit on wages, employee fringe benefits, and depreciation. Companies purchasing products and services from distressed-zone suppliers get a 30% credit (5% for related parties). Enhanced credits of 60% on wages and 50% on purchases apply to facilities repatriated from foreign countries posing supply chain risks and facilities producing population health products. Economically distressed zones are census tracts with poverty rates of 30% or more, or 25% or more with additional economic decline indicators. The bill also amends the Public Health Service Act to expand BARDA authority to support population health products that protect vulnerable populations during pandemics, and requires federal agencies to ensure timely delivery of approved health products to at-risk individuals.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Incentivize domestic medical manufacturing in economically distressed areas through tax credits for wages, fringe benefits, depreciation, and purchases from distressed zone suppliers, with enhanced credits for repatriated and population health product manufacturing.
Who Benefits
- Pharmaceutical and medical device manufacturers
- Economically distressed communities (including Puerto Rico and territories)
- Domestic medical supply chain
Who Bears Costs
- Federal revenue (foregone tax revenue from credits)
- Foreign medical manufacturers (competitive disadvantage)
Key Policy Areas
{'domain': 'Tax', 'evidence': 'Creates 40% tax credit on wages, fringe benefits, and depreciation for medical manufacturing in economically distressed zones (sections 1400AA-1 through 1400AA-4)'}, {'domain': 'Healthcare', 'evidence': 'Targets medical product manufacturing including drugs, biological products, and devices; amends Public Health Service Act for population health products'}, {'domain': 'Economic Development', 'evidence': 'Designates economically distressed zones based on poverty rates and economic indicators; requires strategic development plans'}
Primary Purpose
Incentivize domestic medical manufacturing in economically distressed areas through tax credits for wages, fringe benefits, depreciation, and purchases from distressed zone suppliers, with enhanced credits for repatriated and population health product manufacturing.
Policy Domains
Legislative Strategy
"Use generous tax credits to incentivize reshoring of medical manufacturing from foreign countries to high-poverty U.S. areas, combining economic development with supply chain security goals"
Sponsors
Legislative Progress
IntroducedMs. Malliotakis (for herself, Mr. Torres of New York, Ms. …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Foreign medical manufacturers, Manufacturers repatriating production from foreign countries, Medical manufacturers sourcing domestically
Positive-direction: Manufacturers repatriating production from foreign countries, Medical manufacturers sourcing domestically, Medical product manufacturers in distressed zones, Pharmaceutical and medical device manufacturers, Population health product manufacturers
Negative-direction: Foreign medical manufacturers
Economically distressed communities, High-poverty census tracts including Puerto Rico
BARDA and pandemic preparedness agencies, Federal revenue
Positive-direction: BARDA and pandemic preparedness agencies
Negative-direction: Federal revenue
Suppliers in economically distressed zones
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of the Treasury
- "secretary_commerce"
- → Secretary of Commerce
- "the_secretary"
- → Secretary of Health and Human Services
Key Definitions
Terms defined in this bill
A census tract with 30%+ poverty rate for 5 years, or 25%+ poverty with additional economic distress indicators and joint designation by Treasury and Commerce secretaries
A widely available drug to diagnose, mitigate, prevent, or treat harm from non-communicable diseases combined with pandemic threats
A facility that researches, develops, or produces medical products or essential components located within an economically distressed zone
A prescription drug, exported drug, nonprescription drug, or medical device subject to FDA regulation
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology